Linzhi Zhang

Statistics

Publications

Citations

106

H-Index

Active since

2021

Affiliations

Chinese PLA General Hospital(Current)

Peking University

Guiyang Medical University

Peking Union Medical College Hospital

Shenzhen University

Linzhi Zhang is an author at Chinese PLA General Hospital specializing in medicine, programmed cell death protein 1 inhibitors, and hepatocellular carcinoma.

ORCID

Publications per year

2021–2023

Publications

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients

Xu Yang, Bowen Chen, Yanyu Wang et al. · Hepatology International · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors

Lei Jin, Tao Yan, Linzhi Zhang et al. · Hepatology International · 2022 · 24 citations

Medicine, Oncology, Pharmacology +17

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study

Bowen Chen, Linzhi Zhang, Jiamin Cheng et al. · Drug Design Development and Therapy · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases

Tong Wu, Linzhi Zhang, Zhen Zeng et al. · OncoTargets and Therapy · 2021 · 10 citations · Full text

Medicine, Immunology, Oncology +17

1–4 of 4